Daraxonrasib has demonstrated significant survival benefits for metastatic PDAC patients who no longer respond to traditional chemotherapy, increasing survival from 6.7 to 13.2 months in recent trials.
Daraxonrasib is changing the game for pancreatic cancer patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to a UT Southwestern article by Todd Aguilera, M.D., Ph.D.
In recent trials, daraxonrasib proved to increase patient survival from 6.7 months-13.2 months. These results were produced in those with metastatic PDAC who “stopped responding to prior chemotherapy.”
Daraxonrasib is a RAS(ON) inhibitor and taken once a day. According to Dr. Aguilera, it is gentler than chemo drugs like gemcitabine and nab-paclitaxelor FOLFIRINOX.
Currently, daraxonrasib can be accessed through clinical trials or the manufacturer’s expanded access program (EAP) (awarded in May of this year). It is important to note that patients cannot take daraxonrasib if they are on any other metastatic PDAC medications.
Dr. Aguilera said, “This drug is the start of more breakthroughs to come, which will give more patients with pancreatic cancer a longer, higher quality of life.”
